NICE recommends olaparib
The National Institute for Health and Care Excellence has recommended olaparib as an option for treating adults with relapsed, platinum sensitive ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum-based chemotherapy (only if they have had three or more courses of platinum-based chemotherapy). The drug cost of olaparib for people who remain on treatment after 15 months must be met by the company.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200586
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com